Clinical evaluation of miconazole tincture in skin mycoses.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Aussems.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In a double blind fully randomised trial, three Belgian dermatologists independently treated 81 patients suffering from various eczematous skin disorders. After four weeks both the dermatologists and their patients assessed the results of a twice-daily topical application of an ointment containing 17 beta-hydroxy-4-estren-3-one-17-decanoate (nandrolone decanoate, Dexatopic) ointment or a reference ointment. Both the dermatologists' and the patients' assessments of the two preparations showed that there was no significant difference between the two treatments although Dexatopic did seem to have a more favourable profile in the "much improved" area. In the total score decrease, there was an indication that Dexatopic had a more favourable effect than the reference preparation.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Seventy-eight patients with tinea corporis or tinea cruris participated in a double-blind study with either 100 mg itraconazole or 500 mg ultramicronized griseofulvin for 15 consecutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% response rate vs. 51%) and at the follow-up visit (91% response vs. 64%). The most important difference between both treatments was the mycologic outcome, for which itraconazole showed a cure rate of 87% compared to 57% for griseofulvin 2 weeks after completion of therapy. It is suggested that 100 mg of itraconazole orally once daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated.
Explore the source record for details and available documents.